{
  "symbol": "BIIB",
  "year": 2022,
  "period": "Y2022",
  "curated_text": "Symbol: BIIB. Year: 2022. Period: Y2022. ReportType: K10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: COVID-19, Solothurn, Content s These, Biogen Inc., MabThera, PLEGRIDY \u00ae, TYSABRI \u00ae, Biogen, BENEPALI, FLIXABI, FUMADERM, IMRALDI, FAMPYRA, Content s PART, BUSINESS Overview Biogen, SMA, TECFIDERA, VUMERITY, AVONEX, TYSABRI, non-Hodgkin's, CLL, Genentech, Inc., Genentech, the Roche Group, ALS, MDD, SLE, CLE, schizophrenia (, CIAS, Samsung Bioepis Co., Ltd., Samsung BioLogics Co., Ltd., Samsung BioLogics, ENBREL, HUMIRA, BYOOVIZ, the European Union, Key Business Developments, BAT1806, IL-6, Bio-Thera Solutions, Content s InnoCare Pharma Limited, InnoCare Pharma Limited, InnoCare, Bruton, RRMS, BIIB115 Option Exercise, ASO, Joint Venture, Samsung Biologics, the U.S. Food and Drug Administration, FDA, Eisai Co., Ltd., Eisai, the Committee for Medicinal Products for Human Use (, the European Medicines Agency, EMA, the Marketing Authorization Application, MAA, CHMP, Medicare, Medicaid Services, CMS, National Coverage Determination (NCD, NCD, Content s BIIB125, Sage Therapeutics, Inc., PPD, New Drug Application, NDA, a Biologics License Application, BLA, Switzerland Manufacturing Facility, Good Manufacturing Practice, GMP, the Swiss Agency for Therapeutic Products, the Executive Committee, Dementia Business Unit, Global Safety and Regulatory Sciences, Research and Development, National Medical Products Administration, Content s VUMERITY, DRF, the European Commission, EC, PLEGRIDY, IM, SC, American Academy of Neurology (, AAN, NOVA, Q4W, Association International Conference, Phase 4, ICARE AD-US, EMBARK, the aducanumab, the E.U. \u2022, the First Committee on New Drugs, the Pharmaceutical Affairs, Food Sanitation Council, the Ministry of Health, Labour and Welfare, OLE, Content s, Phase 2b 201, DEVOTE, Cure SMA Research & Clinical Care Meeting, ASCEND, Evrysdi, KINETIC, WATERFALL, LANDSCAPE, NEST, the European College of Neuropsychopharmacology  Congress, Specialized Immunology Immunology, TOPAZ-1, Phase 2, CONVEY, Content s Biosimilars BAT1806 \u2022, Bio-Thera Solutions, Ltd., Bio-Thera, Samsung BioLogics \u2022, Digital Health \u2022, Apple Inc., Apple Watch, MCI, TheraPanacea, Content s Marketed Products, Interferon, Segment Information, Management's Discussion and Analysis of Financial Condition, Content s Multiple Sclerosis, Alkermes plc, E.U. None U.S., MS Acorda Therapeutics, Inc., Acorda, Alkermes, Neuromuscular Disorders SMA, SMN1, survival motor neuron, SMN, Content, SMA Ionis Pharmaceuticals Inc., Eisai U.S., TNF, Content s Our, Product Indication Major Markets Rheumatoid, Juvenile, Psoriatic, Axial, U.K. Rheumatoid, Psoriasis Paediatric, Crohn\u2019s, Ulcerative colitis Paediatric, Content s Genentech, Product Indication Major Markets Non-Hodgkin's, CLL Rheumatoid, ANCA, Pemphigus, Non-Hodgkin's, CLL Follicular, None Germany Patient Support and Access, Early Access Programs, Trademark Office, the Hatch-Waxman Act, Content s regulatory, the World Trade Organization's, USPTO, Content s Product Territory Patent, FAMPYRA Europe, Crystalline, U.S. 8,361,977 Compositions, U.S. 8,980,853 Compositions, U.S. 9,717,750 Compositions, U.S. 9,926,559 Compositions, Europe 1,910,395 Compositions, Europe 2,548,560 Compositions, Europe 3,305,302 Compositions, Europe 3,308,788 Compositions, Europe 3,449,926 Compositions, Content s (, E.U. 2024, Litigation, inter partes, Content s Competition Competition, Sanofi Genzyme BETASERON/BETAFERON, Bayer Group, glatiramer acetate, Teva Pharmaceuticals Industries Ltd., EXTAVIA, Novartis AG, fingolimod, Sandoz, Johnson & Johnson REBIF, ozanimod, Banner Life Sciences KESIMPTA, Novartis AG Multiple, the European General Court, the General Court\u2019s, RMS, PPMS, OCREVUS, TREANDA, HCL, ARZERRA, IMBRUVICA, ZYDELIG, Rheumatoid Arthritis, ORENCIA, Content s medical, Neuroimmunology, BTK, Phase 1 Neuromuscular Disorders, Phase 1 Neuropsychiatry, Large Hemispheric Infarction, LHI, Business Relationships, Content s Business Relationships, Acorda Therapeutics, Inc., Denali Therapeutics Inc., Denali, LRRK2, Denali\u2019s Transport, Antibody Transport Vehicle: Abeta, Transport Vehicle, Eisai Co., Roche Group, Ionis Pharmaceuticals, AG, Neurimmune SubOne AG, the U.S. Outside, Sangamo Therapeutics, Inc., Sangamo. Context excerpt: competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candi",
  "competition_summary": [
    {
      "competitor": "COVID-19",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Solothurn",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s These",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Biogen Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "MabThera",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "PLEGRIDY \u00ae",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TYSABRI \u00ae",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Biogen",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "BENEPALI",
      "mentions": 8,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "FLIXABI",
      "mentions": 9,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "FUMADERM",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "IMRALDI",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "FAMPYRA",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s PART",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "BUSINESS Overview Biogen",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "SMA",
      "mentions": 19,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TECFIDERA",
      "mentions": 15,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "VUMERITY",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "AVONEX",
      "mentions": 8,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TYSABRI",
      "mentions": 11,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "non-Hodgkin's",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "CLL",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Genentech, Inc.",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Genentech",
      "mentions": 10,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Roche Group",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ALS",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "MDD",
      "mentions": 8,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "SLE",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "CLE",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "schizophrenia (",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "CIAS",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Samsung Bioepis Co., Ltd.",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Samsung BioLogics Co., Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Samsung BioLogics",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ENBREL",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "HUMIRA",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "BYOOVIZ",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the European Union",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Key Business Developments",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "BAT1806",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "IL-6",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Bio-Thera Solutions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s InnoCare Pharma Limited",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "InnoCare Pharma Limited",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "InnoCare",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Bruton",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "RRMS",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "BIIB115 Option Exercise",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ASO",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Joint Venture",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Samsung Biologics",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the U.S. Food and Drug Administration",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "FDA",
      "mentions": 20,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Eisai Co., Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Eisai",
      "mentions": 15,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Committee for Medicinal Products for Human Use (",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the European Medicines Agency",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "EMA",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Marketing Authorization Application",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "MAA",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "CHMP",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Medicare",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Medicaid Services",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "CMS",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "National Coverage Determination (NCD",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "NCD",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s BIIB125",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sage Therapeutics, Inc.",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "PPD",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "New Drug Application",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "NDA",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "a Biologics License Application",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "BLA",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Switzerland Manufacturing Facility",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Good Manufacturing Practice",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "GMP",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Swiss Agency for Therapeutic Products",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Executive Committee",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Dementia Business Unit",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Global Safety and Regulatory Sciences",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Research and Development",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "National Medical Products Administration",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s VUMERITY",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "DRF",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the European Commission",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "EC",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "PLEGRIDY",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "IM",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "SC",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "American Academy of Neurology (",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "AAN",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "NOVA",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Q4W",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Association International Conference",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Phase 4",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ICARE AD-US",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "EMBARK",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the aducanumab",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the E.U. \u2022",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the First Committee on New Drugs",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Pharmaceutical Affairs",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Food Sanitation Council",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Ministry of Health, Labour and Welfare",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "OLE",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Phase 2b 201",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "DEVOTE",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Cure SMA Research & Clinical Care Meeting",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ASCEND",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Evrysdi",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "KINETIC",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "WATERFALL",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "LANDSCAPE",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "NEST",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the European College of Neuropsychopharmacology  Congress",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Specialized Immunology Immunology",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TOPAZ-1",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Phase 2",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "CONVEY",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s Biosimilars BAT1806 \u2022",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Bio-Thera Solutions, Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Bio-Thera",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Samsung BioLogics \u2022",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Digital Health \u2022",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Apple Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Apple Watch",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "MCI",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TheraPanacea",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s Marketed Products",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Interferon",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Segment Information",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Management's Discussion and Analysis of Financial Condition",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s Multiple Sclerosis",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Alkermes plc",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "E.U. None U.S.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "MS Acorda Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Acorda",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Alkermes",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Neuromuscular Disorders SMA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "SMN1",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "survival motor neuron",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "SMN",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "SMA Ionis Pharmaceuticals Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Eisai U.S.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TNF",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s Our",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Product Indication Major Markets Rheumatoid",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Juvenile",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Psoriatic",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Axial",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "U.K. Rheumatoid",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Psoriasis Paediatric",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Crohn\u2019s",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Ulcerative colitis Paediatric",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s Genentech",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Product Indication Major Markets Non-Hodgkin's",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "CLL Rheumatoid",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ANCA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Pemphigus",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Non-Hodgkin's",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "CLL Follicular",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "None Germany Patient Support and Access",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Early Access Programs",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Trademark Office",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Hatch-Waxman Act",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s regulatory",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the World Trade Organization's",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "USPTO",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s Product Territory Patent",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "FAMPYRA Europe",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Crystalline",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "U.S. 8,361,977 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "U.S. 8,980,853 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "U.S. 9,717,750 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "U.S. 9,926,559 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Europe 1,910,395 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Europe 2,548,560 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Europe 3,305,302 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Europe 3,308,788 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Europe 3,449,926 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s (",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "E.U. 2024",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Litigation",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "inter partes",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s Competition Competition",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sanofi Genzyme BETASERON/BETAFERON",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Bayer Group",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "glatiramer acetate",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Teva Pharmaceuticals Industries Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "EXTAVIA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Novartis AG",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "fingolimod",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sandoz",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Johnson & Johnson REBIF",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ozanimod",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Banner Life Sciences KESIMPTA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Novartis AG Multiple",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the European General Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the General Court\u2019s",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "RMS",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "PPMS",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "OCREVUS",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TREANDA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "HCL",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ARZERRA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "IMBRUVICA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ZYDELIG",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Rheumatoid Arthritis",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ORENCIA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s medical",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Neuroimmunology",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "BTK",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Phase 1 Neuromuscular Disorders",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Phase 1 Neuropsychiatry",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Large Hemispheric Infarction",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "LHI",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Business Relationships",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Content s Business Relationships",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Acorda Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Denali Therapeutics Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Denali",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "LRRK2",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Denali\u2019s Transport",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Antibody Transport Vehicle: Abeta",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Transport Vehicle",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Eisai Co.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Roche Group",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Ionis Pharmaceuticals",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "AG",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Neurimmune SubOne AG",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the U.S. Outside",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sangamo Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sangamo",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    }
  ]
}